Treatment aimed at people who cannot be vaccinated is boost to firm’s coronavirus portfolio

AstraZeneca has received UK regulatory approval for its long-acting Covid-19 antibody treatment Evusheld in a boost to its coronavirus portfolio as the British-Swedish drugmaker targets greater drug development success at its new £1bn research lab in Cambridge.

Aimed at preventing Covid infections in people with poor immune systems who cannot be vaccinated, Evusheld is already approved in the US and other countries, and the US government has ordered 1.7m doses.

Continue reading…

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

There will never be a cuttlefish in the cabinet – and that makes me sad | Emma Beddington

Octopuses and their relatives are remarkably clever and controlled. How many of…

Student immigration restrictions will damage UK economy, universities say

With a third fewer students enrolling, university leaders accuse ministers of wanting…

Ariana Grande: Positions review – all-night romps but no climax

The tabloids are frothing about the R&B singer’s ‘steamy’ new direction, but…

Former BBC DJ jailed for stalking Jeremy Vine and others

Alex Belfield was found guilty last month after subjecting victims to ‘avalanche…